CVKD
What one share of Cadrenal Therapeutics holds
Pharmaceutical Preparations
We are a late-stage biopharmaceutical company advancing novel therapies for life-threatening immune and thrombotic conditions. As a result of our acquisition of a 12-lipoxygenase (“12-LOX”) platform of assets in December 2025 (as described in more detail below), we transitioned our primary strategic focus to the development of CAD-1005 for the treatment of immune-mediated and thrombotic disorders.
Cadrenal Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$4.86 |
|---|---|
| Cash and investments | $0.77 |
| Book value | $1.32 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2023 | — | −$9.29 | $0.00 | −$3.93 | — | $8.86 |
| 2024 | — | −$8.73 | $0.01 | −$6.04 | $16.50 | $4.17 |
| 2025 | — | −$6.64 | $0.00 | −$6.32 | $16.50 | $1.17 |